Sens. Charles Grassley, R-Iowa, chair of the Senate Finance Committee, and Herb Kohl, D-Wis., chair of the Senate Special Committee on Aging, are asking Medtronic to provide details about alleged incentives the company provided to physicians in exchange for the use and promotion of the firm's spine products, including off-label use of the Infuse bone graft replacement. The allegations stem from a 2002 lawsuit by former Medtronic legal counsel Ami Kelley, which was sealed by a federal judge but reported on in September and October by the Wall Street Journal. Among the charges cited by Kohl were "improper, if not illegal, payments by Medtronic to surgeons and physicians." Those cited by Grassley included adding doctors' names to patents and providing royalties for devices they did not help to develop. The lawsuit led to a $40 million settlement agreement between Medtronic and the government, which is being challenged in federal court by former Medtronic travel manager Jacqueline Kay Poteet, who said the amount was too low ("1The Gray Sheet" July 24, 2006, p. 3)
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
